Plasmon‐Enhanced Single Extracellular Vesicle Analysis for Cholangiocarcinoma Diagnosis
Advanced Science · 2023
DOI: 10.1002/advs.202205148 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2023. Verfasst von Mi Ho Jeong und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for Systems Biology, Massachusetts General Hospital, Boston, MA, 02114, USA. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Extracellular Vesicles, Bile Duct Neoplasms. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Severance Hospital Research Fund for Clinical Excellence, NIGMS NIH HHS, Ministry of Trade, Industry, and Energy, Republic of Korea.
Abstract (Originalsprache)
Cholangiocarcinoma (CCA) is a fatal disease often detected late in unresectable stages. Currently, there are no effective diagnostic methods or biomarkers to detect CCA early with high confidence. Analysis of tumor‐derived extracellular vesicles (tEVs) harvested from liquid biopsies can provide a new opportunity to achieve this goal. Here, an advanced nanoplasmonic sensing technology is reported, termed FLEX (fluorescence‐amplified extracellular vesicle sensing technology), for sensitive and robust single EV analysis. In the FLEX assay, EVs are captured on a plasmonic gold nanowell surface and immunolabeled for cancer‐associated biomarkers to identify tEVs. The underlying plasmonic gold nanowell structures then amplify EVs’ fluorescence signals, an effective amplification process at the single EV level. The FLEX EV analysis revealed a wide heterogeneity of tEVs and their marker levels. FLEX also detected small tEVs not detected by conventional EV fluorescence imaging due to weak signals. Tumor markers (MUC1, EGFR, and EPCAM) are identified in CCA, and this marker combination is applied to detect tEVs in clinical bile samples. The FLEX assay detected CCA with an area under the curve of 0.93, significantly better than current clinical markers. The sensitive and accurate nanoplasmonic EV sensing technology can aid in early CCA diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Systems Biology, Massachusetts General Hospital, Boston, MA, 02114, USA.
- Division of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
- Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
- Department of Radiology, Massachusetts General Hospital, Boston, MA, 02114, USA.
- Department of Systems Biology, Harvard Medical School, Boston, MA, 02115, USA.
ORCID-Profile: Hyungsoon Im
Förderung
- Severance Hospital Research Fund for Clinical Excellence
- NIGMS NIH HHS
- Ministry of Trade, Industry, and Energy, Republic of Korea
- National Research Foundation of Korea
- NCI NIH HHS
- National Institute of General Medical Sciences
- National Cancer Institute
Zitieren
APA
Jeong, M. H., Son, T., Tae, Y. K., Park, C. H., Lee, H. S., Chung, M. J., Park, J. Y., Castro, C. M., Weissleder, R., Jo, J. H., Bang, S., & Im, H. (2023). Plasmon‐Enhanced Single Extracellular Vesicle Analysis for Cholangiocarcinoma Diagnosis. Advanced Science. https://doi.org/10.1002/advs.202205148
Vancouver
Jeong MH, Son T, Tae YK, Park CH, Lee HS, Chung MJ, et al. Plasmon‐Enhanced Single Extracellular Vesicle Analysis for Cholangiocarcinoma Diagnosis. Advanced Science. 2023. doi:10.1002/advs.202205148
BibTeX
@article{Jeong2023,
author = {Jeong, Mi Ho and Son, Taehwang and Tae, Yoo Keung and Park, Chan Hee and Lee, Hee Seung and Chung, Moon Jae and Park, Jeong Youp and Castro, Cesar M and Weissleder, Ralph and Jo, Jung Hyun and Bang, Seungmin and Im, Hyungsoon},
title = {Plasmon‐Enhanced Single Extracellular Vesicle Analysis for Cholangiocarcinoma Diagnosis},
journal = {Advanced Science},
year = {2023},
doi = {10.1002/advs.202205148}
}
EUVIMED